One area which has particular importance for treatment is whether there is involvement of the meninges around the central nervous system. Risk factors
Most cases of AML do not have exposure to any identified risk factors. However, a number of risk factors for developing AML have been identified. These include other blood disorders, chemical exposures, ionizing radiation, and genetic risk factors. Where a defined exposure to past chemotherapy, radiotherapy, toxin or hematologic malignancy is known, this is termed secondary AML. Other blood disorders
Other blood disorders, particularly myelodysplastic syndrome (MDS) and less commonly myeloproliferative neoplasms (MPN), can evolve into AML; the exact risk depends on the type of MDS/MPN. The presence of asymptomatic clonal hematopoiesis also raises the risk of transformation into AML. Chemical exposure
Exposure to anticancer chemotherapy, in particular alkylating agents, can increase the risk of subsequently developing AML. Other chemotherapy agents, including fludarabine, and topoisomerase II inhibitors are also associated with the development of AML; most commonly after 4–6 years and 1–3 years respectively. These are often associated with specific chromosomal abnormalities in the leukemic cells.Other chemical exposures associated with the development of AML include benzene, chloramphenicol and phenylbutazone. Radiation
High amounts of ionizing radiation exposure, such as that used for radiotherapy used to treat some forms of cancer, can increase the risk of AML. People treated with ionizing radiation after treatment for prostate cancer, non-Hodgkin lymphoma, lung cancer, and breast cancer have the highest chance of acquiring AML, but this increased risk returns to the background risk observed in the general population after 12 years.
Individuals ages 21–40 years are most commonly affected.A 2002 study looking at 445 samples of dermatophytes in patients in Goiânia, Brazil found the most prevalent type to be Trichophyton rubrum (49.4%), followed by Trichophyton mentagrophytes (30.8%), and Microsporum canis (12.6%).A 2013 study looking at 5,175 samples of Tinea in patients in Tehran, Iran found the most prevalent type to be Tinea pedis (43.4%), followed by Tinea unguium. (21.3%), and Tinea cruris (20.7%). See also
Mycobiota

References
Further reading
Weitzman I, Summerbell RC (1995). "The dermatophytes". Clinical Microbiology Reviews. 8 (2): 240–259. doi:10.1128/cmr.8.2.240. PMC 172857. PMID 7621400. External links

Tinea photo library at Dermnet